BCMA-specific ADC MEDI2228 and Daratumumab induce synergistic myeloma cytotoxicity via IFN-driven immune responses and enhanced CD38 expression

CONCLUSIONS: These results provide the basis for clinical evaluation of combination MEDI2228 with Dara to further improve patient outcome in MM.PMID:34301753 | DOI:10.1158/1078-0432.CCR-21-1621

Source: Clinical Cancer Research - July 24, 2021 Category: Cancer & Oncology Authors: Lijie Xing Su Wang Jiye Liu Tengteng Yu Hailin Chen Kenneth Wen Yuyin Li Liang Lin Phillip A Hsieh Shih-Feng Cho Gang An Lugui Qiu Krista Kinneer Nikhil Munshi Kenneth C Anderson Yu-Tzu Tai Source Type: research